Professor Somnath Mukhopadhyay

MD, PhD, FRCPCH

Chair in Paediatrics

Other faculty positions:

Deputy Director of Doctoral Studies

Area of Expertise

Paediatrics - the gene-environmental interactions that regulate eczema and asthma in childhood

Research Area(s)

Paediatrics, Infection & Immunology

Prof Somnath Mukhopadhyay

+44 (0)1273 696955 x2397

s.mukhopadhyay@
bsms.ac.uk

Divisional Assistant:
Judy Keogh
+44 (0)1273 696955 x2409
DA.Paediatrics@
bsms.ac.uk

Royal Alexandra Children's Hospital
Brighton, BN2 5BE

 

Biography

Fellow, Royal College of Paediatrics and Child Health, 2001

Clinical senior lecturer (honorary consultant) in Children’s Respiratory Medicine, Ninewells Hospital, Maternal and Child Health Sciences, University of Dundee, 1997-2007

Wellcome Trust Advanced Research Training Fellow (honorary senior registrar), Department of Child Health, University of Dundee, 1994-1997

Clinical lecturer (honorary senior registrar), Department of Child Health, University of Dundee, 1992-1994

Cystic Fibrosis Clinical Research Fellow (honorary registrar), Royal Hospital for Sick Children, University of Bristol, 1989-1992

Education

MB BS University of Calcutta, India, 1983

Research focus

In a landmark discovery published in Nature Genetics 2006, we described a novel mechanism causing eczema and asthma in children. Subsequent to this, I have described the role of this gene defect on a number of aspects of the development of allergy and asthma in children, e.g. the development of more severe asthma, or interactions with exposure to allergens from pets. The discovery of the role of this protein change, and its subsequent characterization, has potential for future treatments that could reduce the risk of developing eczema and asthma in children.

In another important discovery published in the Journal of Allergy and Clinical Immunology, impact factor 9.2 and reported prominently by Radio 4, ABC, and in paper editions of all leading newspapers in the UK in October 2009, I led research into the detection of a gene change that substantially reduces the efficacy of the commonest asthma medicine, the 'blue inhaler', in children. I have now completed a randomized controlled trial further testing this hypothesis. The results, expected for publication this year, are likely to generate further international interest.

Current research

Our current research aims to further unravel the wider picture of gene-environment interactions and their role in guiding treatment for childhood eczema and asthma.

 

Williams Graphic Design :: sitebysimon :: login